Zhuangzhuang Liu

Zhuangzhuang Liu

Auto-generated profile, based on publicly available information

Zhuangzhuang Liu

Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB-UGent Center for Inflammation Research, Technologiepark-Zwijnaarde 71, Ghent 9052, Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2024 in JHEP Reports
Verified
Journal Article
Open access
FPFederico F. De Ponti
Federico F. De Ponti
ZLZhuangzhuang Liu
Zhuangzhuang Liu
CSCharlotte L. Scott
Charlotte L. Scott
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a spectrum of disease states ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which can eventually lead to the development of cirrhosis and hepatocellular carcinoma. Macrophages have long been implicated in driving the progression from steatosis to end-stage disease, yet we still know relatively little about the precise involvement of these cells in MASLD progression and/or regression. Rather, there are a considerable number of conflicting reports regarding the precise roles of these cells. This confusion stems from the fact that, until recently, macrophages in the liver were considered a homogenous population. However, thanks to recent technological advances including multi-parameter flow cytometry, single-cell RNA sequencing and spatial proteogenomics, we now know that this is not the case. Rather hepatic macrophages, even in the healthy liver, are heterogenous, existing in multiple subsets with distinct transcriptional profiles and hence likely functions. This heterogeneity is even more prominent in MASLD, where the macrophage pool consists of multiple different subsets of resident and recruited cells. To probe the unique functions of these cells and determine if targeting macrophages may be a viable therapeutic strategy in MASLD, we first need to unravel this complexity and decipher which populations and/or activation states are present and what functions each of these may play in driving MASLD progression. In this review, we summarise recent advances in the field, highlighting what is currently known about the hepatic macrophage landscape in MASLD and the questions that remain to be tackled.

1 December 2019 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
RHRong Huang
Rong Huang
GGGuo Guo
Guo Guo
LLLiaoxun Lu
Liaoxun Lu
RFRui Fu
Rui Fu
JLJing Luo
Jing Luo
LZLichen Zhang
Lichen Zhang
Rong Huang, Guo Guo, Liaoxun Lu, Rui Fu, Jing Luo, Zhuangzhuang Liu, Yanrong Gu, Wenyi Yang, Qianqian Zheng, Tianzhu Chao, Le He, Ying Wang, Zhiguo Niu, Hui Wang, Toby Lawrence, Marie Malissen, Bernard Malissen, Yinming Liang, Lichen Zhang

21 December 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LLLiaoxun Lu
Liaoxun Lu
JHJunjian Hu
Junjian Hu
TCTianzhu Chao
Tianzhu Chao
ZCZhijun Chen
Zhijun Chen
ZLZhuangzhuang Liu
Zhuangzhuang Liu
LZLichen Zhang
Lichen Zhang
Schistosomiasis is among the major neglected tropical diseases and effective prevention by boosting the immune system is still not available. T cells are key cellular components governing adaptive immune response to various infections. While common laboratory mice, such as C57BL/6, are highly susceptible to schistosomiasis, the SD rats are extremely resistant. However, whether adaptive immunity is necessary for such natural resistance to schistosomiasis in rats remains to be determined. Therefore, it is necessary to establish genetic model deficient in T cells and adaptive immunity on the resistant SD background, and to characterize liver pathology during schistosomiasis. In this study we compared experimental schistosomiasis in highly susceptible C57BL/6 (B6) mice and in resistant SD rats, using cercariae of Schistosoma japonicum. We observed a marked T cell expansion in the spleen of infected B6 mice, but not resistant SD rats. Interestingly, CD3e−/− B6 mice in which T cells are completely absent, the infectious burden of adult worms was significantly higher than that in WT mice, suggesting an anti-parasitic role for T cells in B6 mice during schistosome infection. In further experiments, we established Lck deficient SD rats by using CRISPR/Cas9 in which T cell development was completely abolished. Strikingly, we found that such Lck deficiency in SD rats severely impaired their natural resistance to schistosome infection, and fostered parasite growth. Together with an additional genetic model deficient in T cells, the CD3e−/− SD rats, we confirmed the absence of T cell resulted in loss of natural resistance to schistosome infection, but also mitigated liver immunopathology. Our further experiments showed that regulatory T cell differentiation in infected SD rats was significantly decreased during schistosomiasis, in contrast to significant increase of regulatory T cells in infected B6 mice. These data suggest that T cell mediated immune tolerance facilitates persistent infection in mice but not in SD rats. The demonstration of an important role for T cells in natural resistance of SD rats to schistosomiasis provides experimental evidences supporting the rationale to boost T cell responses in humans to prevent and treat schistosomiasis.